Page last updated: 2024-08-24

triazoles and azacitidine

triazoles has been researched along with azacitidine in 23 studies

Research

Studies (23)

TimeframeStudies, this research(%)All Research%
pre-19901 (4.35)18.7374
1990's0 (0.00)18.2507
2000's3 (13.04)29.6817
2010's14 (60.87)24.3611
2020's5 (21.74)2.80

Authors

AuthorsStudies
Levi, JA; Wiernik, PH1
Kikuchi, K; Kobayashi, H; Kuriyama, K; Mori, Y; Togashi, T; Tokuji, Y; Yamamoto, N1
Steensma, DP; Tefferi, A1
Ozawa, K1
Albasanz, JL; Barrachina, M; Buira, SP; Dentesano, G; Ferrer, I; Martín, M; Moreno, J1
Tefferi, A1
Miyazaki, Y1
Alimena, G; Breccia, M; Colafigli, G; Federico, V; Finsinger, P; Latagliata, R; Loglisci, G; Petrucci, L; Salaroli, A; Santopietro, M; Serrao, A1
Allen, PB; Baer, MR; Kleinberg, ME; Koka, R1
Kami, M; Kobayashi, K; Nishikawa, Y; Okuda, S; Takebayashi, C; Tanimoto, T1
Guinea de Castro, JM; Moreno de Gusmão, B; Oiartzabal, I; Perez-Persona, E1
Alkhaeir, S; Callens, C; Damaj, G; Dussiot, M; Gorin, NC; Hermine, O; Isnard, F; Marolleau, JP; Monteiro, RC; Moura, IC; Paubelle, E; Rubio, MT; Suarez, F; Zylbersztejn, F1
Tohyama, K1
Bhatnagar, B; Blum, W; Devine, S; Garzon, R; Hofstetter, J; Kauffman, M; Klisovic, R; Marcucci, G; Phelps, MA; Ranganathan, P; Santhanam, R; Shacham, S; Vasu, S; Walker, A; Walsh, K; Yu, X1
Imanishi, S; Ohsuga, M; Ohyashiki, JH; Ohyashiki, K; Takahashi, R1
Arnan, M; Duarte, RF; Pomares, H; Sánchez-Ortega, I; Sureda, A1
Chen, Q; Gu, J; Li, N; Li, S; Wang, W; Wang, X; Wang, Z; Zhao, G1
Estey, EH; Percival, MM1
Ertl, IE; Hassler, MR; Ilijazi, D; Lemberger, U; Shariat, SF1
Pilko, A; Wollman, R; Zhang, T1
Chen, TT; Cheng, FM; Lin, CC; Tien, JZ; Yeh, SP1
Abdel-Wahab, O; Alvarez, K; Chung, SS; Gönen, M; Klimek, VM; Mi, X; Paffenholz, SV; Park, JH; Penson, AV; Rampal, RK; Sen, F; Sigler, A; Stein, EM; Tallman, MS; Taylor, J1
Ding, K; Duan, L; Fu, R; Guo, Y; Liu, Z; Shen, H1

Reviews

6 review(s) available for triazoles and azacitidine

ArticleYear
Risk-based management of myelodysplastic syndrome.
    Oncology (Williston Park, N.Y.), 2007, Volume: 21, Issue:1

    Topics: Anemia, Sideroblastic; Antilymphocyte Serum; Azacitidine; Benzoates; Decitabine; Deferasirox; DNA Modification Methylases; Enzyme Inhibitors; Erythropoietin; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Histone Deacetylase Inhibitors; Humans; Immunosuppressive Agents; Interleukin-11; Iron Chelating Agents; Lenalidomide; Leukemia, Myelomonocytic, Chronic; Myelodysplastic Syndromes; Prognosis; Risk; Stem Cell Transplantation; Thalidomide; Triazoles

2007
[Pathophysiology, diagnosis and treatment of anemia].
    Nihon rinsho. Japanese journal of clinical medicine, 2008, Volume: 66, Issue:3

    Topics: Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Azacitidine; Benzoates; Deferasirox; Diagnosis, Differential; Hematopoietic Stem Cell Transplantation; Humans; Iron Chelating Agents; Lenalidomide; Thalidomide; Triazoles

2008
[MDS].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 2012, Volume: 53, Issue:1

    Topics: Azacitidine; Benzoates; Clinical Trials as Topic; Cytokines; Deferasirox; Drug Therapy, Combination; Humans; Lenalidomide; Myelodysplastic Syndromes; Thalidomide; Thrombopoietin; Treatment Outcome; Triazoles

2012
[Myelodysplastic syndromes: treatment strategy up-to-date].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 2014, Volume: 55, Issue:1

    Topics: Antilymphocyte Serum; Azacitidine; Benzoates; Cyclosporine; Cytarabine; Deferasirox; Disease Progression; Drug Discovery; Drug Therapy, Combination; Erythropoietin; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Immunosuppressive Agents; Iron Chelating Agents; Lenalidomide; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Quality of Life; Risk Assessment; Thalidomide; Triazoles

2014
Current treatment strategies for measurable residual disease in patients with acute myeloid leukemia.
    Cancer, 2019, Sep-15, Volume: 125, Issue:18

    Topics: Aminopyridines; Aniline Compounds; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Immunological; Azacitidine; Cytogenetic Analysis; Decitabine; Enzyme Inhibitors; Flow Cytometry; Hematopoietic Stem Cell Transplantation; Humans; Hydrazines; Immunologic Factors; In Situ Hybridization, Fluorescence; Lenalidomide; Leukemia, Myeloid, Acute; Molecular Diagnostic Techniques; Neoplasm, Residual; Nivolumab; para-Aminobenzoates; Protein Kinase Inhibitors; Pyrazines; Pyrrolidines; Recombinant Fusion Proteins; Remission Induction; Transplantation, Homologous; Triazines; Triazoles

2019
Epigenetic alterations of testicular germ cell tumours.
    Current opinion in urology, 2020, Volume: 30, Issue:2

    Topics: Antineoplastic Agents; Azacitidine; Azepines; Biomarkers, Tumor; Cinnamates; DNA Methylation; Epigenesis, Genetic; Humans; Imidazoles; Male; MicroRNAs; Neoplasms, Germ Cell and Embryonal; RNA, Untranslated; Testicular Neoplasms; Triazoles

2020

Trials

2 trial(s) available for triazoles and azacitidine

ArticleYear
A comparative clinical trial of 5-azacytidine and guanazole in previously treated adults with acute nonlymphocytic leukemia.
    Cancer, 1976, Volume: 38, Issue:1

    Topics: Acute Disease; Adolescent; Adult; Aged; Azacitidine; Digestive System; Female; Fever; Guanazole; Humans; Infusions, Parenteral; Leukemia; Leukopenia; Male; Middle Aged; Remission, Spontaneous; Time Factors; Triazoles

1976
Safety and activity of selinexor in patients with myelodysplastic syndromes or oligoblastic acute myeloid leukaemia refractory to hypomethylating agents: a single-centre, single-arm, phase 2 trial.
    The Lancet. Haematology, 2020, Volume: 7, Issue:8

    Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Hydrazines; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Patient Safety; Prognosis; Survival Rate; Triazoles

2020

Other Studies

15 other study(ies) available for triazoles and azacitidine

ArticleYear
Formation of embryogenic cell clumps from carrot epidermal cells is suppressed by 5-azacytidine, a DNA methylation inhibitor.
    Journal of plant physiology, 2005, Volume: 162, Issue:1

    Topics: 2,4-Dichlorophenoxyacetic Acid; Azacitidine; Cell Differentiation; Daucus carota; DNA Methylation; Dose-Response Relationship, Drug; Gene Expression Regulation, Developmental; Gene Expression Regulation, Plant; Plant Epidermis; Triazoles

2005
DNA methylation regulates adenosine A(2A) receptor cell surface expression levels.
    Journal of neurochemistry, 2010, Volume: 112, Issue:5

    Topics: Azacitidine; Cell Line; Chromatin Immunoprecipitation; DNA Methylation; Dose-Response Relationship, Drug; Enzyme Inhibitors; Gene Expression Regulation; HeLa Cells; Humans; Immunoprecipitation; Methyl-CpG-Binding Protein 2; Neuroblastoma; Protein Binding; Radioligand Assay; Receptor, Adenosine A2A; Receptors, Cell Surface; RNA, Messenger; S-Adenosylmethionine; Time Factors; Triazines; Triazoles; Tritium

2010
Myelodysplastic syndromes--many new drugs, little therapeutic progress.
    Mayo Clinic proceedings, 2010, Volume: 85, Issue:11

    Topics: Age Distribution; Antimetabolites, Antineoplastic; Antineoplastic Agents; Azacitidine; Benzoates; Deferasirox; Humans; Iron Chelating Agents; Lenalidomide; Myelodysplastic Syndromes; Survival Analysis; Thalidomide; Triazoles

2010
Deferasirox treatment for myelodysplastic syndromes: "real-life" efficacy and safety in a single-institution patient population.
    Annals of hematology, 2012, Volume: 91, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Antimetabolites; Azacitidine; Benzoates; Chelating Agents; Deferasirox; Drug Eruptions; Drug Evaluation; Drug Therapy, Combination; Female; Follow-Up Studies; Gastrointestinal Diseases; Hematinics; Humans; Iron Overload; Kidney Diseases; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Retrospective Studies; Thalidomide; Treatment Outcome; Triazoles

2012
Scedosporium apiospermum soft tissue infection as the initial presentation of acute myeloid leukemia: a case report.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Mar-01, Volume: 31, Issue:7

    Topics: Aged, 80 and over; Amputation, Surgical; Antifungal Agents; Antimetabolites, Antineoplastic; Azacitidine; Bone Marrow; Decitabine; Diagnosis, Differential; Disease Progression; Fatal Outcome; Female; Humans; Leg Ulcer; Leukemia, Myeloid, Acute; Mycoses; Pancytopenia; Pyrimidines; Scedosporium; Soft Tissue Infections; Triazoles; Voriconazole

2013
A case of late onset erythropoietic protoporphyria associated with myelodysplastic syndrome treated by the combination of beta carotene and azacitidine.
    Annals of hematology, 2013, Volume: 92, Issue:10

    Topics: Aged; Azacitidine; Benzoates; beta Carotene; Deferasirox; Humans; Male; Myelodysplastic Syndromes; Protoporphyria, Erythropoietic; Triazoles

2013
[Transfusional independence in a patient with refractory anemia with excess blasts-2 refractory to 5-azacitidine treated with deferasirox and colony stimulating factors].
    Medicina clinica, 2014, Jan-21, Volume: 142, Issue:2

    Topics: Aged; Anemia, Refractory, with Excess of Blasts; Azacitidine; Benzoates; Blood Transfusion; Chelation Therapy; Combined Modality Therapy; Deferasirox; Disease Progression; Drug Resistance; Epoetin Alfa; Erythropoietin; Fatal Outcome; Granulocyte Colony-Stimulating Factor; Humans; Iron; Iron Chelating Agents; Leukemia, Myeloid, Acute; Male; Recombinant Proteins; Triazoles

2014
Deferasirox and vitamin D improves overall survival in elderly patients with acute myeloid leukemia after demethylating agents failure.
    PloS one, 2013, Volume: 8, Issue:6

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Benzoates; Case-Control Studies; Cell Differentiation; Deferasirox; DNA (Cytosine-5-)-Methyltransferases; Drug Resistance, Neoplasm; Drug Synergism; Female; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Myeloid Cells; Proportional Hazards Models; Retrospective Studies; Treatment Outcome; Triazoles; Vitamin D

2013
Decitabine priming enhances the antileukemic effects of exportin 1 (XPO1) selective inhibitor selinexor in acute myeloid leukemia.
    Blood, 2015, Apr-23, Volume: 125, Issue:17

    Topics: Active Transport, Cell Nucleus; Animals; Antineoplastic Agents; Azacitidine; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p21; Decitabine; DNA Methylation; DNA Modification Methylases; Exportin 1 Protein; Forkhead Box Protein O3; Forkhead Transcription Factors; Humans; Hydrazines; Karyopherins; Leukemia, Myeloid, Acute; Mice; Mice, Inbred NOD; Mice, SCID; Receptors, Cytoplasmic and Nuclear; Triazoles; Tumor Cells, Cultured; Up-Regulation

2015
Effect of combined deferasirox and 5-azacytidine treatment on human leukemia cells in vitro.
    Annals of hematology, 2015, Volume: 94, Issue:9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Benzoates; Deferasirox; HL-60 Cells; Humans; Iron Chelating Agents; Leukemia; Triazoles; U937 Cells

2015
Invasive fungal infections in AML/MDS patients treated with azacitidine: a risk worth considering antifungal prophylaxis?
    Mycoses, 2016, Volume: 59, Issue:8

    Topics: Aged; Aged, 80 and over; Antibiotic Prophylaxis; Antifungal Agents; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Female; Humans; Invasive Fungal Infections; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic-Myeloproliferative Diseases; Neutropenia; Numbers Needed To Treat; Retrospective Studies; Risk Factors; Tomography, X-Ray Computed; Triazoles

2016
Synergistic inhibitory effects of deferasirox in combination with decitabine on leukemia cell lines SKM-1, THP-1, and K-562.
    Oncotarget, 2017, May-30, Volume: 8, Issue:22

    Topics: Antimetabolites, Antineoplastic; Apoptosis; Azacitidine; Benzoates; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Decitabine; Deferasirox; Drug Synergism; Gene Expression Regulation; Humans; Iron Chelating Agents; Leukemia; Reactive Oxygen Species; Triazoles

2017
Loci specific epigenetic drug sensitivity.
    Nucleic acids research, 2020, 05-21, Volume: 48, Issue:9

    Topics: Acetylation; Azacitidine; Azepines; Chromosomes, Human; DNA Methylation; Epigenesis, Genetic; Genes, Reporter; Genetic Loci; Genomics; Histones; Humans; K562 Cells; Sequence Analysis, DNA; Triazoles

2020
Venetoclax plus cytochrome P450 inhibitors without ramp-up strategy led to low risk of tumor lysis syndrome in acute myeloid leukemia.
    Annals of hematology, 2020, Volume: 99, Issue:9

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Child; Creatinine; Cytochrome P-450 Enzyme Inhibitors; Drug Administration Schedule; Drug Synergism; Female; Humans; Hyperuricemia; Leukemia, Myeloid, Acute; Male; Middle Aged; Retrospective Studies; Sulfonamides; Triazoles; Tumor Lysis Syndrome; Urate Oxidase; Uric Acid; Young Adult

2020
Selinexor synergizes with azacitidine to eliminate myelodysplastic syndrome cells through p53 nuclear accumulation.
    Investigational new drugs, 2022, Volume: 40, Issue:4

    Topics: Azacitidine; Humans; Hydrazines; Myelodysplastic Syndromes; Neoplasms; Triazoles; Tumor Suppressor Protein p53

2022